How Tech Giants like NVIDIA, Google, and Microsoft Are Targeting New Niches in Biopharma R&D

Tech giants are becoming part of biopharma’s infrastructure, applying AI, data, and cloud to drug discovery as they seek footholds in new markets.

Large technology companies aren’t newcomers to biopharma and healthcare, but now there’s less theater around “disruption” and more attention to infrastructure: compute, data pipelines, modeling capacity, and the task of fusing systems together. The running theme is scale, defensibility, and sometimes, salvage.

In July, Deloitte released a report Trends Shaping Biopharma in 2025, highlighting two big changes.

• The first is that data and AI have become the new competitive advantage. With healthcare data growing rapidly and AI tools advancing, pharma companies can no longer just react to patient needs. They must predict them, provide proactive support, and design personalized treatments. Many firms are already bringing patient services in-house, and more than half of industry leaders admit their business models need to be updated.

• The second change is the rise of smarter supply chains and manufacturing. Geopolitical risks and supply chain disruptions are pushing companies to adapt, and technologies like digital supply networks, cloud platforms, digital twins, and advanced analytics are starting to reshape how drugs are produced—making the process faster, leaner, and more resilient.

In this article: Alphabet/Google — Amazon — Apple — Microsoft — NVIDIA — Meta — Intel — IBM — Samsung — Oracle — Big Tech, Biopharma and Society

Topic: Tech Giants